Evidence map›Paper›PMID 42180546›Full record

ArticleActa pharmaceutica Sinica. B2026

DeepICER: A deep learning framework for predicting compound-induced gene expression profiles.

Fanbo Meng, Can Wang, Yue Lin, Jing Mo, Xunzhi Zhang, Zhaotong Cong, Chi Song, Sanyin Zhang, Shilin Chen, Liang Leng and 1 more

Abstract read
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fanbo MengSchool of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Can WangInnovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Yue LinSchool of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Jing MoCollege of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China.
Xunzhi ZhangSchool of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Zhaotong CongInnovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Chi SongInnovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Sanyin ZhangInnovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Shilin ChenInnovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Liang LengInnovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Wei ChenSchool of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate prediction of drug-induced gene expression profiles is crucial for phenotype-based drug discovery. Although computational methods have shown potential, they struggle with the complexities of varying doses and durations. To overcome these limitations, we developed DeepICER, a model that predicts gene expression profiles induced by chemical perturbations across any dose and duration. Utilizing a bilinear attention mechanism, DeepICER captures the interplay between dose, duration, and basal gene expression, enabling accurate predictions for novel compounds and cell lines. DeepICER outperforms existing models with superior flexibility in handling any dose and duration and accuracy, achieving a 45.1% improvement in predictive performance. Experimental validation confirmed that PD-166285, identified by DeepICER, exhibits stronger inhibitory effects on A549 cells compared to paclitaxel. To enhance accessibility, DeepICER is developed as an online platform, providing researchers with a tool to predict gene expression in compound-treated cells, thereby advancing drug repurposing and accelerating drug discovery.

Indexed as

Bilinear attention mechanismChemical perturbationsDeep learningDrug discoveryGene expression profile

Identifiers

PMID42180546
PMCPMC13198338

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.